Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SVRA 
Savara Inc (SVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: SVRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.31
1 Year Target Price $10.31
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.29% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 762.21M USD | Price to earnings Ratio - | 1Y Target Price 10.31 |
Price to earnings Ratio - | 1Y Target Price 10.31 | ||
Volume (30-day avg) 8 | Beta 0.46 | 52 Weeks Range 1.89 - 4.50 | Updated Date 10/29/2025 |
52 Weeks Range 1.89 - 4.50 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.13 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.04% | Return on Equity (TTM) -99.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 486500857 | Price to Sales(TTM) 131146 |
Enterprise Value 486500857 | Price to Sales(TTM) 131146 | ||
Enterprise Value to Revenue 11.91 | Enterprise Value to EBITDA -4.76 | Shares Outstanding 172836922 | Shares Floating 91203527 |
Shares Outstanding 172836922 | Shares Floating 91203527 | ||
Percent Insiders 5.49 | Percent Institutions 98.04 |
Upturn AI SWOT
Savara Inc
Company Overview
History and Background
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Founded in 2011, it has evolved through clinical trials and strategic pipeline development, focusing on inhalation therapies.
Core Business Areas
- Molgradex: Development of Molgradex for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease.
- Aironyl: Development of Aironyl (inhaled ciprofloxacin) for nontuberculous mycobacterial (NTM) lung infections.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives. The organizational structure is typical of a clinical-stage biotech company, emphasizing R&D and clinical operations.
Top Products and Market Share
Key Offerings
- Molgradex: Molgradex is Savara's lead product candidate for aPAP. While direct market share data is unavailable due to its investigational status, the aPAP market is underserved with limited approved therapies. Competitors include off-label therapies like whole lung lavage.
- Aironyl: Aironyl, targeting NTM lung infections, is another key product candidate. Similar to Molgradex, specific market share data is not available pre-approval. Competitors include existing antibiotic regimens.
Market Dynamics
Industry Overview
The biopharmaceutical industry for rare diseases is growing, driven by unmet medical needs and orphan drug designations which provide market exclusivity.
Positioning
Savara Inc. positions itself as a leader in rare respiratory diseases, focusing on inhaled therapies with potential for significant clinical impact.
Total Addressable Market (TAM)
The TAM for aPAP is estimated in the hundreds of millions globally, while the TAM for NTM lung infections is larger, potentially exceeding $1 billion. Savara is positioned to capture a significant portion of these markets with successful product approvals.
Upturn SWOT Analysis
Strengths
- Focus on rare respiratory diseases
- Strong pipeline of inhaled therapies
- Potential for orphan drug designation
- Experienced management team
Weaknesses
- Clinical trial risks
- Dependence on regulatory approvals
- Limited commercial infrastructure
- Requires additional funding to continue operations
Opportunities
- Potential for multiple product approvals
- Expansion into new respiratory indications
- Partnerships with larger pharmaceutical companies
- Increasing awareness of rare diseases
Threats
- Competition from other pharmaceutical companies
- Changes in regulatory environment
- Failure to obtain regulatory approvals
- Unfavorable clinical trial results
- Patent expirations
Competitors and Market Share
Key Competitors
- HLGN
- INSG
Competitive Landscape
Savara faces competition from companies developing therapies for similar respiratory conditions. Its inhaled delivery approach could provide a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by pipeline advancement and clinical trial milestones.
Future Projections: Future growth depends on the successful commercialization of Molgradex and Aironyl. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Molgradex and Aironyl, and seeking strategic partnerships.
Summary
Savara is a clinical-stage company focused on rare respiratory diseases, which is a high-risk/high-reward scenario. Its pipeline of inhaled therapies holds promise, particularly Molgradex, however, it is dependent on positive clinical outcomes and regulatory approvals. Savara needs to continue to manage its cash flow and secure partnerships to support its development programs. The overall market for rare respiratory diseases provides opportunities for growth if the company overcomes its development challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Savara Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Savara Inc
Exchange NASDAQ | Headquaters Langhorne, PA, United States | ||
IPO Launch date 2017-06-01 | Chairman & CEO Mr. Matthew Pauls J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.savarapharma.com |
Full time employees 59 | Website https://www.savarapharma.com | ||
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.